Hinge Health, Inc. provides a technology platform for digital health care, with a core focus on musculoskeletal conditions. The company combines an AI-powered care model, wearable devices, motion-tracking technology and access to clinicians to deliver personalized, evidence-based care for members and cost-management programs for employer, public-sector and health-plan clients.
News about Hinge Health commonly covers quarterly results and guidance, client expansion, outcomes research for chronic pain programs, and product development. Recurring updates also include the FDA-cleared Enso wearable device, the company’s Migraine Care Program, public-sector adoption of its MSK care platform, board and governance changes, and capital actions tied to its Class A common stock.
Hinge Health (NYSE: HNGE) reported strong Q2 2025 financial results, with revenue surging 55% year-over-year to $139.1 million. The company demonstrated robust growth metrics, including a 32% increase in client base to 2,359 and LTM calculated billings of $568.4 million, up 55% from Q2 2024.
The company's financial performance showed mixed results, with a GAAP loss from operations of $580.7 million, largely due to $591.0 million in stock-based compensation expense. However, non-GAAP income from operations was positive at $26.1 million. The company maintained strong liquidity with $415.1 million in cash and equivalents.
Looking ahead, Hinge Health provided guidance for Q3 2025 with expected revenue between $141-143 million and full-year 2025 revenue projected at $548-552 million, representing 41% year-over-year growth at the midpoint.
Hinge Health (NYSE:HNGE) has scheduled its second quarter 2025 financial results announcement for August 5, 2025, after market close. The company will host an earnings conference call at 1:30 PM PT / 4:30 PM ET on the same day to discuss its quarterly performance and provide guidance.
Investors can access the live audio webcast through the company's investor relations website at ir.hingehealth.com. A replay of the webcast will be made available on the website following the presentation.
Hinge Health (NYSE: HNGE) has announced the pricing of its Initial Public Offering (IPO), offering 13,666,000 shares of Class A common stock at $32.00 per share. The offering consists of 8,522,528 shares from Hinge Health and 5,143,472 shares from selling stockholders. Trading is set to begin on the NYSE on May 22, 2025, under the ticker "HNGE".
The selling stockholders have granted underwriters a 30-day option to purchase up to 2,049,900 additional shares. The company plans to use the proceeds primarily to cover tax obligations related to restricted stock units. Morgan Stanley, Barclays, and BofA Securities are serving as lead book-running managers for the offering.